These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 1012347)

  • 21. Metabolism and excretion of ropivacaine in humans.
    Halldin MM; Bredberg E; Angelin B; Arvidsson T; Askemark Y; Elofsson S; Widman M
    Drug Metab Dispos; 1996 Sep; 24(9):962-8. PubMed ID: 8886605
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Spironolactone metabolism in normal subjects and in patients with liver cirrhosis.
    Váradi A; Fehér T; Bodrogi L; Koref O
    Arzneimittelforschung; 1977; 27(8):1618-20. PubMed ID: 578759
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Disposition of 3H-enisoprost, a gastric antisecretory prostaglandin, in healthy humans.
    Allan LM; Hawkins AJ; Vose CW; Firth J; Brownsill RD; Steiner JA
    Xenobiotica; 1987 Oct; 17(10):1233-46. PubMed ID: 3424870
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics of spironolactone, canrenone and canrenoate-K in humans.
    Sadée W; Dagcioglu M; Schröder R
    J Pharmacol Exp Ther; 1973 Jun; 185(3):686-95. PubMed ID: 4712657
    [No Abstract]   [Full Text] [Related]  

  • 25. Metabolism and excretion of methylproscillaridin by man.
    Rietbrock N; Staud R
    Eur J Clin Pharmacol; 1975 Aug; 8(6):427-32. PubMed ID: 1233244
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [THIN-LAYER CHROMATOGRAPHIC STUDIES OF 3'-(3-OXO-7-ALPHA-ACETYLTHIO-17-BETA-HYDROXY-4-ANDROSTEN-17-ALPHA-YL)-PROPIONIC ACID GAMMA-LACTONE AND ITS METABOLITES IN MAN].
    ZICHA L; WEIST F; SCHEIFFARTH ; SCHMID E
    Arzneimittelforschung; 1964 Jun; 14():699-705. PubMed ID: 14249070
    [No Abstract]   [Full Text] [Related]  

  • 27. Validation of plasma and urinary canrenone for determination of bioavailability of spironolactone--comparison of tablets with solution/suspension.
    Tidd MJ; Ramsay LE; Shelton JR; Palmer RF
    Int J Clin Pharmacol Biopharm; 1977 May; 15(5):205-10. PubMed ID: 873663
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Metabolic disposition of prostaglandin E1 in man.
    Rosenkranz B; Fischer C; Boeynaems JM; Frölich JC
    Biochim Biophys Acta; 1983 Feb; 750(2):231-6. PubMed ID: 6683104
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Metabolism of labetalol by animals and man.
    Martin LE; Hopkins R; Bland R
    Br J Clin Pharmacol; 1976 Aug; 3(4 Suppl 3):695-710. PubMed ID: 990152
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Enhancement by food of canrenone bioavailability from spironolactone.
    Melander A; Danielson K; Scherstén B; Thulin T; Wåhlin E
    Clin Pharmacol Ther; 1977 Jul; 22(1):100-3. PubMed ID: 872489
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Determination of canrenone, the major metabolite of spironolactone, in plasma and urine by high-performance liquid chromatography.
    Krause W; Karras J; Jakobs U
    J Chromatogr; 1983 Oct; 277():191-9. PubMed ID: 6643605
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Preparation of metabolites of spironolactone by microbial oxygenation.
    Marsheck WJ; Karim A
    Appl Microbiol; 1973 Apr; 25(4):647-9. PubMed ID: 4699222
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [On the pharmacokinetics of spironolactone in the elderly].
    Abshagen U; Platt D; Horn HJ
    Klin Wochenschr; 1981 Aug; 59(16):909-10. PubMed ID: 7278082
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics of intravenous and oral 1,2-O-isopropylidene-3-O-3'-(N',N'-dimethylamino-n-propyl)-D-glucofuranose hydrochloride in the dog as a function of dose and characterization of metabolites.
    Garrett ER; Van Peer A
    J Pharm Sci; 1983 Sep; 72(9):1045-57. PubMed ID: 6631692
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Disposition of beta-methyldigoxin in man.
    Rietbrock N; Abshagen U; Bergmann K; Rennekamp H
    Eur J Clin Pharmacol; 1975 Dec; 9(2-3):105-14. PubMed ID: 1233258
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Metabolism and time-course excretion of murideoxycholic acid, a 6 beta-hydroxylated bile acid, in humans.
    Khallou J; Legrand-Defretin V; Parquet M; Coste T; Rautureau J; Lutton C
    J Hepatol; 1993 Mar; 17(3):364-72. PubMed ID: 8315264
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Metabolism, pharmacokinetics, and excretion of a nonpeptidic substance P receptor antagonist, ezlopitant, in normal healthy male volunteers: characterization of polar metabolites by chemical derivatization with dansyl chloride.
    Prakash C; O'Donnell J; Khojasteh-Bakht SC
    Drug Metab Dispos; 2007 Jul; 35(7):1071-80. PubMed ID: 17431029
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetics of 14C-fenflumizole after intravenous administration to man.
    Vinge E; Midskov C; Arnold E
    Acta Pharmacol Toxicol (Copenh); 1986 May; 58(5):355-62. PubMed ID: 3739729
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biotransformation of the mineralocorticoid receptor antagonists spironolactone and canrenone by human CYP11B1 and CYP11B2: Characterization of the products and their influence on mineralocorticoid receptor transactivation.
    Schiffer L; Müller AR; Hobler A; Brixius-Anderko S; Zapp J; Hannemann F; Bernhardt R
    J Steroid Biochem Mol Biol; 2016 Oct; 163():68-76. PubMed ID: 27125452
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics of 14C-radioactivity after oral intake of a single dose of 14C-labeled fampridine (4-aminopyridine) in healthy volunteers.
    Blight AR; Henney HR
    Clin Ther; 2009 Feb; 31(2):328-35. PubMed ID: 19302905
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.